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Brief overview : The RASSF family of tumour 
suppressor genes (TSG) encode Ras superfamily 
effector proteins that, amongst other functions, mediate 
some of the growth inhibitory functions of Ras 
proteins. Several members of this family are inactivated 
by promoter DNA hypermethylation in a broad range 
of cancers, and the RASSF6 gene may be a frequent 
target of epigenetic inactivation in leukaemias. The 
RASSF6 protein is involved in the regulation of 
apoptosis partly by controlling the function of the 
proapoptotic mammalian serine/threonine kinases 1 and 
2 (MST1 and MST2) and modulator of apoptosis 1 
(MOAP-1). 
 
Figure 1: RASSF6 gene structure. The RASSF6 gene is composed of at least two isoforms that are transcribed from immediately 
upstream (RASSF6A) or from within (RASSF6B) a small CpG island. 
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DNA/RNA 
Description 
The RASSF6 gene occupies 47478 bp of genomic 
DNA. RASSF6A [GenBank:NM_201431] contains 11 
exons and is transcribed 82 bp upstream from a small 
(214 bp) 5' CpG island (at chr4:74,486,045-
74,486,258). RASSF6B [GenBank:NM_177532] 
contains 11 exons and is transcribed from within the 
same CpG island. There is evidence of additional splice 
variants and transcription initiation sites for the 
RASSF6 gene, however these have not been validated. 
Protein 
Description 
RASSF6A [GenBank:NP_958834] is a 369 amino acid 
protein whereas RASSF6B [GenBank:NP_803876] is a 
337 amino acid protein. The RASSF6A protein (figure 
2) contains C-terminal Ras-association (RA) and 
Sav/RASSF/Hpo (SARAH) domains that define the 
'classical' RASSF family (RASSF1, RASSF2, 
RASSF3, RASSF4, RASSF5, RASSF6). The 
RASSF6B protein lacks the N-terminal 32 amino acids 
present in RASSF6A but is otherwise identical. There 
are some inconsistencies in the literature regarding 
which may be the major isoform, however all 
functional work to date has studied the larger 369 
amino acid protein, which is hereafter referred to as 
RASSF6. Using an in-house antibody Ikeda et al., 
(2007) were unable to detect endogenous RASSF6 
protein. All functional work has been performed using 
overexpressed RASSF6 protein. A commercially 
available antibody towards RASSF6 (ProteinTech 
Group) has been used to demonstrate re-expression 
following treatment with the DNA demethylating agent 
5-aza-2'deoxycytidine (5azaDC) and Trichostatin A 
(TSA) in leukaemia cell lines in which RASSF6 is 
epigenetically inactivated (Hesson et al., 2009). 
Expression 
Northern blotting of a normal tissue RNA panel shows 
RASSF6 mRNA is highly expressed in thymus, kidney 
and placenta, with lower levels of expression in colon, 
small intestine and lung (Allen et al., 2007). In the 
same study the matched normal tissue from a primary 
tumour cDNA panel showed readily detectable levels 
of RASSF6 expression in rectal, pancreatic, liver, 
breast and stomach tissues. There has been no 
systematic analysis of the expression patterns of the 
different RASSF6 isoforms. RT-PCR analysis of a 
range of tumour cell lines showed that RASSF6 is 
highly expressed in HeLa and A549 cells with lower 
levels observed in MCF-7, U373, H1299 and HepG2 
(Ikeda et al., 2007). It appears from these studies that 
the tissue distribution of RASSF6 expression is much 
more restricted than that of the RASSF members 
RASSF1, RASSF2 and RASSF5.  
Expression of the RASSF6 gene is lost or 
downregulated in a variety of solid tumours by 
unknown mechanisms, whereas in childhood 
leukaemias RASSF6 is inactivated by CpG island 
promoter region DNA methylation (see below). 
Function 
dRASSF antagonises the Hippo pathway 
In Drosophila, dRASSF represents the orthologue of 
mammalian RASSF1-6. dRASSF protein competes 
with Salvador (the Drosophila orthologue of the 
mammalian WW45 protein) for binding to Hippo (the 
Drosophila orthologue of the mammalian MST 
kinases). The dRASSF-Hippo and Salvador-Hippo 
interactions appear mutually exclusive and control 
Hippo function in very different ways. 
 
Figure 2: RASSF6 transcript and protein structure. The RASSF6A mRNA (red bar) encodes a 369 amino acid protein 
[GenBank:NP_958834] containing a C-terminal Ras-association (RA) domain of the RalGDS/AF-6 variety and acidic coiled-coil 
Sav/RASSF/Hpo (SARAH) domain. RASSF6B [GenBank:NP_803876] is a predicted 337 amino acid protein lacking the N-terminal 32 
amino acids present in RASSF6A. 
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Both Salvador or dRASSF are stabilised following 
binding to Hippo, however, probing of 
immunoprecipitates of Salvador or dRASSF with a 
phospho-specific antibody that recognises active Hippo 
demonstrates that Hippo is present in Drosophila cells 
in two pools; an active form associated with Salvador 
and an inactive form associated with dRASSF 
(Polesello et al., 2006). Furthermore, RNAi-mediated 
dRASSF depletion led to a marked increase in Hippo 
activation following Staurosporine (STS) treatment, a 
potent activator of Hippo in Drosophila cells and MSTs 
in mammalian cells. Thus, in Drosophila dRASSF 
restricts the activation of Hippo, which may account for 
the smaller size of dRASSF mutant flies (Polesello et 
al., 2006). 
Regulation of apoptosis by mammalian RASSF6 
Several studies have demonstrated that overexpression 
of RASSF6 induces apoptosis and inhibits the growth 
of a variety of tumour cell lines (Ikeda et al., 2007; 
Allen et al., 2007; Ikeda et al., 2009). In HeLa cells 
RASSF6-induced apoptosis occurred through both 
caspase-dependent and caspase-independent pathways, 
since overexpression of RASSF6 results in cleavage 
and activation of caspase-3 but apoptosis was not 
abrogated by z-VAD-FMK, an inhibitor of caspase-1, 
caspase-3, caspase-4 and caspase-7 activation (Ikeda et 
al., 2007). RASSF6 also induced Bax activation and 
cytochrome C release as well as the release of 
apoptosis-inducing factor (AIF) and endonuclease G 
(endoG) from the mitochondria. Following release 
from the mitochondria AIF and endoG may result in 
DNA fragmentation even in the absence of caspase 
activation. Early evidence has suggested that the 
molecular mechanisms of RASSF6-induced apoptosis 
are likely to be complex and multi-layered. Currently, 
three signalling routes are implicated in RASSF6-
induced apoptosis (see below), though at present it is 
unclear whether these routes act autonomously or as 
part of an extensive apoptotic network. 
RASSF6 is an effector molecule of K-Ras-mediated 
apoptosis 
RASSF6 interacts with K-Ras in a GTP-dependent 
manner via its Ras-association domain and the effector 
domain of K-Ras. Therefore, RASSF6 exhibits the 
basic properties of a Ras effector protein. These data 
are in contradiction to another report in which RASSF6 
did not interact with K-Ras, H-Ras, N-Ras, M-Ras or 
TC21 under the same conditions that RASSF5 binds to 
these Ras proteins (Ikeda et al., 2007). Apart from a 
strict context-dependency of these interactions The 
reasons for this discrepancy is unclear but may be 
related to a strict context-dependency of the interaction 
or to the requirement of Ras farnesylation as shown by 
Allen et al., (2007). Of particular note however, is the 
observation that RASSF6 acts synergistically with 
activated K-Ras to induce cell death in 293-T cells 
(Allen et al., 2007). Taken together these data suggests 
RASSF6 does indeed function within a K-Ras-
regulated pathway, most likely through direct 
interaction, to determine cell fate. 
RASSF6 negatively regulates the proapoptotic 
protein MST2 
RASSF6 interacts with MST2 via the Sav/RASSF/Hpo 
(SARAH) domains within both proteins (Ikeda et al., 
2009). It seems clear from many studies that several (if 
not all) classical RASSF proteins interact with the 
MST1 and MST2 kinases and that this interaction is at 
least partly involved in RASSF-induced apoptosis (van 
der Weyden and Adams, 2007). Ikeda et al., (2009) 
showed that the SARAH domain of MST2 can bind 
both WW45 (the mammalian orthologue of the 
Drosophila protein Salvador) and RASSF6 to form a 
trimeric complex. However, RASSF6 and WW45 do 
not interact. This differs somewhat with the regulation 
of the Hippo pathway in Drosophila, in which the 
Salvador/Hippo and dRASSF/Hippo complexes are 
mutually exclusive (see above). RASSF6 inhibits 
MST2 kinase activity, however activation of MST2 
releases RASSF6 in a manner dependent on WW45. 
Previous studies have demonstrated that MST2 can 
extensively phosphorylate WW45 (Callus et al., 2006). 
Ikeda et al., (2009) demonstrated that activation of 
MST2 by the phosphatase inhibitor okadaic acid (OA) 
reduced the co-immunoprecipitation of RASSF6 with 
MST2, whilst the association of MST2 and WW45 
remained unchanged. Taken together this suggests that 
the activation of MST2 and subsequent 
phosphorylation of WW45 results in the release of 
RASSF6 from the WW45/MST2/RASSF6 complex. 
The release of RASSF6 was shown to be WW45-
dependent since RASSF6 remained in complex with 
MST2 following OA treatment of cells in which 
WW45 had been depleted by RNAi. Furthermore, the 
release of RASSF6 appears to be necessary for 
RASSF6-mediated apoptosis. However, apoptosis was 
vastly reduced in cells transfected with both MST2 and 
RASSF6. This block of RASSF6-induced apoptosis 
was dependent on the SARAH domain of MST2 but 
not the kinase activity of MST2 suggesting that MST2 
blocks RASSF6-mediated apoptosis by physical 
interaction. Interestingly co-expression of RASSF6, 
MST2 and WW45 resulted in potent cell death. This 
effect was dependent on the SARAH domain of WW45 
suggesting that physical interaction of WW45 with 
MST2 was necessary to reinstate RASSF6-induced 
apoptosis by allowing the release of RASSF6. 
Inhibition of MST2 kinase activity by RASSF6 also 
results in the inhibition of NDR1 and LATS2 
phosphorylation (Ikeda et al., 2009). NDR1 and LATS2 
are known MST2 substrates that form part of the 
MST/Hippo tumour suppressor pathway (see 
Hergovich and Hemmings, 2009 and Harvey and 
Tapon, 2007 for a more thorough review of the 
regulation of apoptosis through the MST/Hippo 
pathway). Thus release of RASSF6 from the MST2-
WW45 complex allows RASSF6-mediated and MST2-
mediated apoptosis (figure 3). The induction of 
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apoptosis through these separate pathways may explain 
the caspase-dependent and caspase-independent nature 
of RASSF6-mediated apoptosis, since full activation of 
MSTs is thought to require caspase cleavage. 
MOAP-1 is involved in RASSF6-mediated apoptosis 
The MOAP-1 protein may also be a RASSF6 effector 
molecule. To date, two independent studies have 
demonstrated that RASSF6 also interacts with MOAP-
1 (Allen et al., 2007; Ikeda et al., 2009). Though this 
interaction has not been demonstrated formally at the 
endogenous level, co-expression of the two proteins 
clearly demonstrates that MOAP-1 is a likely mediator 
of RASSF6-induced apoptosis in a manner independent 
of the MST/Hippo tumour suppressor pathway. 
MOAP-1 regulates the 'extrinsic' pathway of apoptosis 
by acting downstream of death receptors such as the 
tumour necrosis factor a receptor 1 (TNF-R1) and 
TNFa apoptosis-inducing related ligand receptor 1 
(TRAIL-R1). A role for MOAP-1 in regulating 
RASSF1A-induced apoptosis has previously been 
demonstrated. Following ligand binding the C-terminal 
region of MOAP-1 associates with the death domain of 
TNF-R1. Subsequently, the TNF-R1/MOAP-1 receptor 
complex is internalised and recruits RASSF1A through 
the N-terminal cysteine-rich (C1) domain within 
RASSF1A (Baksh et al., 2005; Vos et al., 2006; Foley 
et al., 2008). Under 'static' conditions MOAP-1 is held 
in an inactive conformation, however binding to 
RASSF1A results in a conformational change that 
allows MOAP-1 to interact with Bax. This in turn 
induces a conformational change within Bax that is 
required for its insertion into the mitochondrial 
membrane and for the release of inner mitochondrial 
membrane proteins that can induce apoptosis. 
Interestingly, activated K-Ras, RASSF1A and MOAP-
1 synergise to induce Bax activation and  
apoptosis (Vos et al., 2006) indicating that cell death 
induced by the RASSF1A/MOAP-1 interaction may be 
regulated by both K-Ras and death receptors. 
The acidic sequence Glu-Glu-Glu-Glu [
312
EEEE] in the 
SARAH domain of RASSF1A that binds to MOAP-1 
(Baksh et al., 2005) is also partially conserved in the 
RASSF6 SARAH domain [EEEK]. However, this is 
unlikely to be the sole site of interaction since RASSF6 
lacking the N-terminal region, the Ras-association 
domain, or the SARAH domain also interacted with 
MOAP-1 (Ikeda et al., 2009). Depletion of MOAP-1 
partially suppresses RASSF6-mediated apoptosis and 
co-expression of MST2 vastly reduces the co-
immunoprecipitation of RASSF6 and MOAP-1; an 
effect that is abrogated by the expression of WW45. 
Taken together these data suggest that the 
MST2/WW45 complex binds RASSF6 and prevents its 
interaction with MOAP-1. The MST-Hippo pathway 
and the MOAP-1 pathway represent distinct RASSF6-
regulated apoptotic pathways that are triggered by the 
activation of MST2 (figure 3). 
Homology 
RASSF6 is one of 10 members of the Ras-association 
domain family (RASSF) comprising RASSF1-10 
(please refer to figure 3 of the RASSF2 gene card. 
RASSF1-6 are termed the 'classical' RASSF family and 
contain C-terminal RA and SARAH domains. 
Consequently, RASSF1-6 are most similar in sequence 
within their C-termini. RASSF7, RASSF8, RASSF9 
and RASSF10 represent evolutionarily conserved but 
structurally distinct RASSF members that lack the 
SARAH domains and contain N-terminal RA domains. 
RASSF7-10 are termed the 'N-terminal' RASSF family. 
Many of these RASSF members are involved in 
tumourigenesis and several (RASSF1A, RASSF2, 
RASSF4, RASSF5A, RASSF6 and RASSF10) are 
inactivated in a variety of human cancers (Hesson et 
al., 2007; van der Weyden and Adams, 2007; Hesson et 
al., 2009). RASSF6 also has orthologues in several 
species (table 1) including Drosophila melanogaster, 
which is the orthologue of the human RASSF1-6 genes. 
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Figure 3: The molecular basis of RASSF6-induced apoptosis. Multiple lines of evidence suggest that RASSF6-induced apoptosis 
involves multiple pathways. K-Ras, MST2 and MOAP-1 have all been implicated in RASSF6-induced apoptosis. To date RASSF1, 
RASSF2, RASSF4, RASSF5 and RASSF6 have been shown to bind to the MST1 and MST2 kinases. Thus, the RASSF proteins play a 
major role in regulating apoptosis through the MST/Hippo tumour suppressor pathway leading to apoptosis. The regulation of apoptosis 
through activation of the TNF-R1 and TRAIL-R1 death receptor pathways has been shown to involve the interaction of RASSF1A with 
MOAP-1. This interaction leads to the release of inner mitochondrial membrane proteins that result in apoptosis. RASSF6 also interacts 
with MOAP-1, though the events downstream have not been fully elucidated. The release of inner mitochondrial membrane proteins is a 
major facet of RASSF6-induced apoptosis therefore it seems likely that RASSF6 regulates MOAP-1 function in a similar way to 
RASSF1A and may feed into the same pathway. The synergistic effects of activated K-Ras, RASSF6 and MOAP-1 overexpression 
suggests that apoptosis through the RASSF6/MOAP-1 complex may be at least partially K-Ras-regulated. 
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Loss of RASSF6 expression in cancer. 
Disease 
Northern blotting analysis showed RASSF6 expression 
is lost or downregulated in 30-60% of primary tumour 
tissues of the breast, colon, kidney, liver, pancreas, 
stomach and thyroid (Allen et al., 2007). The 
mechanisms underlying this reduced expression are not 
clear and, at least in solid tumours, loss of RASSF6 
expression is not associated with promoter DNA 
methylation (Allen et al., 2007). Other mechanisms of 
gene silencing such as histone modifications or long-
range epigenetic silencing may account for RASSF6 
downregulation, but this has not been investigated. In 
childhood leukaemias silencing of RASSF6 expression 
by promoter hypermethylation appears to be an 
extremely frequent event and was identified in 94% 
(48/51) B-ALL and 41% (12/29) T-ALL (Hesson et al., 
2009). To date this remains the first and only 
description of a mechanism accounting for the loss of 
RASSF6 expression in cancer but further suggests that 
epigenetic inactivation of RASSF6 may be specific to 
leukaemias. Further evidence that the loss of RASSF6 
expression is important in cancer is provided in a study 
by Finn et al., (2007), which demonstrated 
downregulation of RASSF6 expression in malignant 
versus benign thyroid tissue. 
Pancreatic endocrine tumour 
Note 
RASSF6 is downregulated in the pancreatic endocrine 
tumour cell line BON1 following siRNAi of Achaete-
scute complex-like 1 (ASCL1), a basic helix loop helix 
(bHLH) transcription factor regulated by the NOTCH 
signalling pathway (Johansson et al., 2009). ASCL1 






Atlas Genet Cytogenet Oncol Haematol. 2011; 15(1)   53 
also negatively regulates expression of Dickkopf 
homologue 1 (DKK1), an antagonist of the Wnt/beta-
catenin-dependent signalling pathway. 
Breast cancer 
Note 
Using an in vitro model of breast carcinogenesis, 
human non-tumourigenic immortalised breast epithelial 
cell line MCF-10A cells were selected following 
exposure to the mutagen ICR191 to create transformed 
cells (Zientek-Targosz et al., 2008). One of the genes 
found to contain a frameshift mutation following this 
selection was RASSF6. The authors postulate that this 
indicates that inactivation of RASSF6 may be involved 
in the transformation of breast epithelial cells thus 




RASSF6 is downregulated in mature B-cells in 
response to B-cell activating factor (BAFF) treatment 
(Saito et al., 2008). BAFF is a tumour necrosis factor 
(TNF) superfamily member, which is thought to be 
involved in the survival and maturation of B-cells 
partly by inhibiting apoptosis. This finding reiterates 
the potential importance of the frequent epigenetic 
inactivation of RASSF6 in childhood B-ALL (Hesson 




Genetic mapping studies have linked the RASSF6 
locus to viral-induced bronchiolitis, the most common 
cause of infant hospital admissions in the industrialised 
world (Hull et al., 2004; Smyth and Openshaw, 2006). 
The 250 kb interval at 4q13.3 implicated by Hull et al., 
(2004) includes three genes (AFM, RASSF6 and IL8), 
however it is unclear which gene is the important 
player. The predominant cause of acute viral 
bronchiolitis is infection with the respiratory syncytial 
virus (RSV). A major consequence of RSV infection is 
stimulation of the NF-kappaB pathway (Hull et al., 
2004), which is thought to modulate the degree of 
inflammation and support viral replication, perhaps by 
suppressing apoptosis (Bitko et al., 2004). Using an 
NF-kappaB luciferase reporter system in A549 lung 
tumour cells it has been found that RASSF6 can 
suppress the serum-induced basal levels of NF-kappaB 
reporter expression by approximately fivefold (Allen et 
al., 2007). Therefore, RASSF6 remains a promising 






Heavy metal detoxification 
Note 
Expression of murine Rassf6 was upregulated 
following subcutaneous injection of Cadmium, possibly 
implicating Rassf6 in the cellular mechanisms of heavy 
metal detoxification (Wimmer et al., 2005). However, 
it seems equally likely that the observed upregulation 
of Rassf6 could be due to increased apoptosis caused 
by the toxic effects of heavy metal exposure. 
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